Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Indivior Pharmaceuticals delivered robust second quarter 2026 financial results, highlighted by a 14% year-over-year increase in total net revenue to $343 million and 21% growth in flagship SUBLOCADE net revenue. Record GAAP and non-GAAP net incomes and a 111% rise in adjusted EBITDA from the prior year underscore operational strength. The company …